CRTH Award Winning Study Demonstrates Malignancy Risks for CLL Patients

Award-winning study on other malignancies in the history of CLL shows that patients that have been treated with fludarabine and cyclophosphamide with/without rituximab had a higher risk of developing myelodysplastic syndrome & acute myeloid leukemia as well as a correlation with certain solid tumor types. Hence, Doctor Thomas Chatzikonstantinou elaborates on the clinical implications of this study for both specialists and patients to consider these risks when choosing therapeutic treatment for CLL.